Wuxi Hisky Medical Technology Co Ltd
8
3
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
100%
1 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
Role: collaborator
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
Role: lead
LivQ-box® Parameters in the Diagnosis of Liver Inflammation
Role: lead
Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study
Role: collaborator
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Role: collaborator
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Role: lead
Effect of Dietary Interventions on Intestinal Flora and Metabolism
Role: lead
Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis
Role: lead
All 8 trials loaded